Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 4:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,016 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Systemic Infection Clear all
Terminated Phase 2Phase 3 Interventional Results available

INB03 for the Treatment of Pulmonary Complications From COVID-19

NCT04370236
View directory record Official record
Conditions
COVID-19
Interventions
INB03, Placebo
Drug
Lead sponsor
Inmune Bio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
9
States / cities
Jonesboro, Arkansas • Louisville, Kentucky • Kosciusko, Mississippi + 4 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 29, 2026, 4:06 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Interferon-Gamma 1b in Patients With Candidemia

NCT04979052
View directory record Official record
Conditions
Candidemia
Interventions
Interferon Gamma-1B
Drug
Lead sponsor
Radboud University Medical Center
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 29, 2026, 4:06 AM EDT
Completed Phase 3 Interventional

Efficacy & Safety of Resatorvid in Adults With Severe Sepsis

NCT00143611
View directory record Official record
Conditions
Sepsis
Interventions
Resatorvid, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
49
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2012 · Synced Oct 29, 2026, 4:06 AM EDT
Completed No phase listed Observational

Optimizing Clinical Use of Polymyxin B

NCT02682355
View directory record Official record
Conditions
Pneumonia, Blood Stream Infection, Urinary Tract Infections, Respiratory Tract Infection (Including Tracheobronchitis), Sepsis
Interventions
Not listed
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
3
States / cities
Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 2, 2024 · Synced Oct 29, 2026, 4:06 AM EDT
Completed Phase 2 Interventional Results available

Acetaminophen and Ascorbate in Sepsis: Targeted Therapy to Enhance Recovery

NCT04291508
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Critical Illness, Respiratory Failure, Sepsis
Interventions
Intravenous Acetaminophen (room temperature), Intravenous Vitamin C (refrigerated), 5% Dextrose (room temperature), 5% Dextrose refrigerated
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
488 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
41
States / cities
Birmingham, Alabama • Tucson, Arizona • Fresno, California + 34 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2024 · Synced Oct 29, 2026, 4:06 AM EDT
Completed Not applicable Interventional

Indirect Calorimetry Usage and Effect in Ventilator-free Days and Muscle Thickness in Septic Ventilated Patients

NCT03440593
View directory record Official record
Conditions
Sepsis, Critical Illness, Respiratory Failure, Nutrition Disorders, Calorie Deficiency, Diaphragm Injury, Quadriceps Muscle Atrophy
Interventions
Caloric delivery will target results of IC measurement.
Other
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Oct 29, 2026, 4:06 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Selepressin Evaluation Programme for Sepsis-Induced Shock - Adaptive Clinical Trial

NCT02508649
View directory record Official record
Conditions
Septic Shock
Interventions
selepressin, placebo
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
868 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
17
States / cities
Colorado Springs, Colorado • Idaho Falls, Idaho • Chicago, Illinois + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2021 · Synced Oct 29, 2026, 4:06 AM EDT
Completed No phase listed Observational

Prospective Observational Study on the Incidence of Opportunistic Fungal Infections

NCT05707156
View directory record Official record
Conditions
Pneumocystis Jirovecii Infection, Pneumocystis, Cryptococcosis, Candidiasis, Aspergillosis
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
12,032 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 2, 2025 · Synced Oct 29, 2026, 4:06 AM EDT
Withdrawn Phase 1 Interventional

A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Systemic Lupus Erythematosus

NCT06429800
View directory record Official record
Conditions
Lupus Nephritis, Systemic Lupus Erythematosus
Interventions
ATA3219
Drug
Lead sponsor
Atara Biotherapeutics
Industry
Eligibility
18 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Thousand Oaks, California
Source: ClinicalTrials.gov public record
Updated Apr 24, 2025 · Synced Oct 29, 2026, 4:06 AM EDT
Completed No phase listed Observational Results available

Effect of Emergency Department Care Reorganization on Door-to-antibiotic Times for Sepsis (LDS SWARM)

NCT03226366
View directory record Official record
Conditions
Septic Shock, Sepsis
Interventions
Immediate evaluation by multidisciplinary team
Other
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years and older
Enrollment
3,230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
4
States / cities
Murray, Utah • Riverton, Utah • Salt Lake City, Utah + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2020 · Synced Oct 29, 2026, 4:06 AM EDT
Completed Phase 3 Interventional Results available

Open-Label Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) in Patients With Candidiasis Caused by Candida Auris (CARES)

NCT03363841
View directory record Official record
Conditions
Candidiasis, Invasive, Candidemia
Interventions
SCY-078
Drug
Lead sponsor
Scynexis, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Jersey City, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 3, 2024 · Synced Oct 29, 2026, 4:06 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Provider Perspectives on Beta-lactam Therapeutic Drug Monitoring Programs in the Critically Ill

NCT04755777
View directory record Official record
Conditions
Sepsis, Critical Illness
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
2
States / cities
Gainesville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Oct 29, 2026, 4:06 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Oral Infections: Dietary Regulation of Local and Systemic Inflammatory Responses

NCT00632957
View directory record Official record
Conditions
Periodontal Attachment Loss
Interventions
Omega-3 Fatty acid (with SRP or OHI), Placebo
Dietary Supplement
Lead sponsor
University of Kentucky
Other
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 12, 2011 · Synced Oct 29, 2026, 4:06 AM EDT
Completed Phase 3 Interventional

Investigation of the Efficacy and Safety of Drotrecogin Alfa (Activated) in Pediatric Severe Sepsis

NCT00049764
View directory record Official record
Conditions
Sepsis
Interventions
Drotrecogin alfa (activated), Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
Up to 17 Years
Enrollment
474 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
23
States / cities
Birmingham, Alabama • Tucson, Arizona • Tuscon, Arizona + 20 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2007 · Synced Oct 29, 2026, 4:06 AM EDT
Completed Phase 4 Interventional Results available

Prophylactic Antimicrobial Catheter Lock

NCT00571259
View directory record Official record
Conditions
Bacteremia
Interventions
Heparin 1000U/mL, 4% Sodium Citrate with Gentamicin 320 mcg/mL
Drug
Lead sponsor
Satellite Healthcare
Other
Eligibility
Not listed
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Mountain View, California
Source: ClinicalTrials.gov public record
Updated Sep 22, 2021 · Synced Oct 29, 2026, 4:06 AM EDT
Completed Not applicable Interventional

Study of an Electronic Health Record-embedded Severe Sepsis Early Warning Alert

NCT02376842
View directory record Official record
Conditions
Severe Sepsis
Interventions
Severe sepsis early warning best practice alert, Standard care
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
1,149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 17, 2015 · Synced Oct 29, 2026, 4:06 AM EDT
Completed Phase 1 Interventional

A Study of the Systemic Absorption of MOB015B

NCT03244280
View directory record Official record
Conditions
Onychomycosis
Interventions
MOB015B
Drug
Lead sponsor
Moberg Pharma AB
Industry
Eligibility
12 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 3, 2018 · Synced Oct 29, 2026, 4:06 AM EDT
Not yet recruiting Phase 2 Interventional

THiamine for Recovery In Vulnerable Early-life Infections

NCT07868679
View directory record Official record
Conditions
Meningitis, Bacteremia
Interventions
thiamine hydrochloride 100 mg, Placebo
Drug · Other
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
Up to 12 Months
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
2
States / cities
Boston, Massachusetts • Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 29, 2026, 4:06 AM EDT
Completed No phase listed Observational

Urinary Heparanase Activity as a Predictor of Acute Kidney Injury in Critically Ill Adults

NCT01900275
View directory record Official record
Conditions
Sepsis, Trauma, Shock, Acute Kidney Injury
Interventions
Urine collection
Other
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 24, 2014 · Synced Oct 29, 2026, 4:06 AM EDT
Recruiting Not applicable Interventional

Vancomycin Reduction Practices (VRP) in the NICU

NCT06772675
View directory record Official record
Conditions
Antibiotic Stewardship, Neonatal Sepsis, Late-Onset, Vancomycin
Interventions
External Facilitation
Behavioral
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
13
States / cities
Modesto, California • Oakland, California • Roseville, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 29, 2026, 4:06 AM EDT
Completed No phase listed Observational

Immune Suppression and Ventilator Associated Pneumonias

NCT01135277
View directory record Official record
Conditions
Sepsis
Interventions
Not listed
Lead sponsor
Matthew Exline
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Oct 29, 2026, 4:06 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

PatientSpot Formerly Known as ArthritisPower

NCT03840928
View directory record Official record
Conditions
Rheumatoid Arthritis, Ankylosing Spondylitis, Fibromyalgia, Gout, Crohn Disease, Juvenile Idiopathic Arthritis, Lupus Erythematosus, Myositis, Osteoarthritis, Osteoporosis, Psoriasis, Psoriatic Arthritis, Scleroderma, Dermatomyositis, Inflammatory Bowel Diseases, Polymyositis, Axial Spondyloarthritis, Diffuse Idiopathic Skeletal Hyperostosis, Polymyalgia Rheumatica, Giant Cell Arteritis, Temporal Arteritis, Wegener, Relapsing Polychondritis, Undifferentiated Connective Tissue Disease, Spinal Cord Injuries, Alzheimer Disease, Amyotrophic Lateral Sclerosis, Ataxia, Bell Palsy, Brain Tumor, Cerebral Aneurysm, Epilepsy, Guillain-Barre Syndrome, Headache, Head Injury, Hydrocephalus, Lumbar Disc Disease, Meningitis, Multiple Sclerosis, Muscular Dystrophy, Neurocutaneous Syndromes, Parkinson Disease, Stroke, Cluster Headache, Tension-Type Headache, Chronic Obstructive Pulmonary Disease, Asthma, Lung Cancer, Cystic Fibrosis, Sleep Apnea, Eczema, Alopecia, Chronic Inflammation, Unstable Angina, Heart Attack, Heart Failure, Arrythmia, Valve Heart Disease, High Blood Pressure, Congenital Heart Disease, Peripheral Arterial Disease, Diabetes, Chronic Liver Disease, Obesity
Interventions
Not listed
Lead sponsor
Global Healthy Living Foundation
Other
Eligibility
19 Years and older
Enrollment
40,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2025
U.S. locations
1
States / cities
Upper Nyack, New York
Source: ClinicalTrials.gov public record
Updated Dec 13, 2023 · Synced Oct 29, 2026, 4:06 AM EDT
Completed Phase 1 Interventional

Pharmacokinetics (PK) of Antistaphylococcal Antibiotics in Infants (NICHD-2012-02-Staph Trio)

NCT01728363
View directory record Official record
Conditions
Systemic Infection
Interventions
Antibiotic
Drug
Lead sponsor
Phillip Brian Smith
Other
Eligibility
14 Days to 32 Weeks
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
10
States / cities
Gainesville, Florida • Jacksonville, Florida • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 29, 2026, 4:06 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Pharmacology of Exenatide in Pediatric Sepsis

NCT01573806
View directory record Official record
Conditions
Septic Shock, Inflammation, Glucose Homeostasis, Organ Dysfunction, Health-related Quality of Life
Interventions
Exenatide, Exenatide vehicle
Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
1 Month to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Oct 29, 2026, 4:06 AM EDT